{"id":946395,"date":"2026-03-23T16:33:29","date_gmt":"2026-03-23T20:33:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"modified":"2026-03-23T16:33:29","modified_gmt":"2026-03-23T20:33:29","slug":"vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","title":{"rendered":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON, March  23, 2026  (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio\u2019s common stock and restricted stock units (\u201cRSUs\u201d) representing the right to receive an aggregate of 46,235 shares of Vor Bio\u2019s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the \u201cInducement Plan\u201d).<\/p>\n<p align=\"justify\">The stock options have a ten-year term and exercise prices that range from $7.95 to $24.11 per share, which equal the closing price of Vor Bio\u2019s common stock on the respective grant dates of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees\u2019 continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees\u2019 continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.<\/p>\n<p align=\"justify\">\n        <strong>About Vor Bio<\/strong>\n      <\/p>\n<p align=\"justify\">Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjI2ZjhlOTMtMjQ0OC00NDQ3LThkOTUtYjNlMzQyOGVjODVmLTEyMTM3MDUtMjAyNi0wMy0yMy1lbg==\/tiny\/Vor-Biopharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media &amp; Investor Contacts:\r\nCarl\u00a0Mauch\r\ncmauch@vorbio.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio\u2019s common stock and restricted stock units (\u201cRSUs\u201d) representing the right to receive an aggregate of 46,235 shares of Vor Bio\u2019s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the \u201cInducement Plan\u201d). The stock options &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946395","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio\u2019s common stock and restricted stock units (\u201cRSUs\u201d) representing the right to receive an aggregate of 46,235 shares of Vor Bio\u2019s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the \u201cInducement Plan\u201d). The stock options &hellip; Continue reading &quot;Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T20:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-03-23T20:33:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"wordCount\":308,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"name\":\"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\",\"datePublished\":\"2026-03-23T20:33:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_locale":"en_US","og_type":"article","og_title":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, March 23, 2026 (GLOBE NEWSWIRE) &#8212; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio\u2019s common stock and restricted stock units (\u201cRSUs\u201d) representing the right to receive an aggregate of 46,235 shares of Vor Bio\u2019s common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the \u201cInducement Plan\u201d). The stock options &hellip; Continue reading \"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-23T20:33:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-03-23T20:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"wordCount":308,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","name":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=","datePublished":"2026-03-23T20:33:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njc2MyM3NDk4NzEzIzIyMDIxNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vor-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946395"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946395\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}